On March 26, 2012, both the Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) announced the resolution of enforcement actions against Biomet Inc. a US entity, which manufactures and sells global medical devices around the world. It is headquartered in Fort Wayne, Indiana. The Company admitted to a lengthy run of bribery and corruption of doctors to purchase its products. The FCPA Blog reported that the “company will pay a criminal fine of $17.3 million to resolve charges brought by the DOJ. It also agreed with the SEC to settle civil charges by paying $5.5 million in disgorgement of profits and pre-judgment interest.” In this post I will review the SEC Complaint and discuss the facts it posited regarding the Company’s internal auditors to draw out some lessons for an Internal Audit Department’s role in Foreign Corrupt Practices Act (FCPA) compliance programs.
Please see full publication below for more information.